Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome

Japanese Journal of Clinical Oncology

Volumn 46, Issue 1, 2016, Pages 31-39

  Ohno, Makoto ^a   Narita, Yoshitaka ^a   Miyakita, Yasuji ^a   Matsushita, Yuko ^a   Arita, Hideyuki ^a,b   Yonezawa, Motoki ^a   Yoshida, Akihiko ^a   Fukushima, Shintaro ^a,c   Takami, Hirokazu ^c   Ichimura, Koichi ^c   Shibui, Soichiro ^a,d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Glioblastoma; IDH1 2; MGMT; Prognostic factor; Temozolomide

Indexed keywords

BEVACIZUMAB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; GUANINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; O-(6)-METHYLGUANINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HUMAN; JAPANESE (PEOPLE); KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIVARIATE ANALYSIS; OLIGODENDROGLIA; OUTCOME ASSESSMENT; PROMOTER REGION; PYROSEQUENCING; SURVIVAL TIME; SYMPTOM; AGED; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME DELETION; ENZYMOLOGY; GENETICS; JAPAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DACARBAZINE; DNA METHYLATION; FEMALE; GLIOBLASTOMA; GUANINE; HUMANS; ISOCITRATE DEHYDROGENASE; JAPAN; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84954522998     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv170     Document Type: Article

References (24)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
2. Li J, Wang M, WonM, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2010;81:623-30.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
4. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 2012;29:131-9.
5. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-83.
6. Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. J Neurosurg 2013;118:1176-80.
7. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-7.
8. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482-90.
9. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-7.
10. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27:5743-50.
11. Yan W, Zhang W, You G, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 2012;7:e30339.
12. Hartmann C, Hentschel B, WickW, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18.
13. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010;119:487-94.
14. Leibetseder A, Ackerl M, Flechl B, et al. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol 2013;15:112-21.
15. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014;16:1263-73.
16. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th edn. Lyon: International Agency for Research on Cancer (IARC). 2007.
18. Pope WB, Sayre J, Perlina A, et al. MR imaging correlates of survival in patients with high-grade gliomas. AJNR AmJ Neuroradiol 2005;26:2466-74.
19. Arita H, Narita Y, Matsushita Y, et al. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 2015;32:22-30.
20. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013;126:267-76.
21. Okita Y, Narita Y, Miyakita Y, et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol 2012;41: 1325-36.
22. OhnoM, Narita Y, Miyakita Y, et al. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas. Brain Tumor Pathol 2013;30:224-32.
23. Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurg Focus 2014;37: E13.
24. Lalezari S, Chou AP, Tran A, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 2013;15:370-81.